The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo

Acta Microbiologica et Immunologica Hungarica

Volumn 55, Issue 1, 2008, Pages 15-31

  Kerek, F ^b   Szegli, G ^a   Cremer, Lidia ^a   Lupu, Andreea Roxana ^a   Durbaca, Steliana ^a   Calugaru, Ana ^a   Herold, Aurora ^a   Radu, D L ^a  

^a CANTACUZINO INSTITUTE   (Romania)

^b DoNatur GmbH   (Germany)

Author keywords

Anti inflammatory; Antibody production; Arthritis drug; TLR agonists

Indexed keywords

MUS;

EID: 42149093874     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.55.2008.1.2     Document Type: Article

References (27)

1. Milbradt, A. G., Kerek, F., Moroder, L., Renner, C.: Structural characterization of Hellethionins from Helleborus purpurascens. Biochemistry 42, 2404-2411 (2003).
2. Stanescu-Rautzoiu, L., Nica, S. A.: Randomised double-blind phase II study with injection containing MCS-18 versus placebo in the treatment of Painful Shoulder Periarthritis. Clinical Trial Report CI-R39-DN-03, 1-216 (2006).
3. Iiguez, M. A., Punzn, C. F. M.: Induction of Cyclooxygenase-2 on activated T lymphocytes: Regulation of T Cell activation by Cyclooxygenase-2 inhibitors. J Immunol 163, 111-119 (1999).
4. Xu, L., Zhang, L., Yi, Y., Kang, H. K., Datta, S. K.: Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nature Med 10, 411-415 (2004).
5. Kouya, Y., Hiroyuki, U., Yoshiki, H., Rie, Y., Hirohisa, T., Hideyuki, H., Yoki, M., Shin, Y.: Effect on nonsteroidal antiinflammatory drug Indomethacin on Th1 and Th2 immune responses in mice. J Pharm Sci 92, 1723-1729 (2003).
6. Ryan, E. P., Pollak, S. J., Murant, T. J., Bernstein, S. H., Felga, R. E., Phipps, R. P.: Activated human B lymphocytes express cyclooxygenase-2 and ciclooxygenase inhibitors attenuate antibody production. J Immunol 174, 2619-2626 (2005).
7. Tarlinton, D.: B-cell memory: are subsets necessary? Nature Review Immunology 6, 785-790 (2006).
8. 4. Molecular Immunology 33(1), 33-45 (1996).
9. Colonna, M., Trinchieri, G., Liu, Y. J.: Plasmocytoid dendritic cells in immunity. Nature Immunology 5(12), 1219-1226 (2004).
10. Kubo, T., Hatton, R. D., Oliver, J., Liu, X., Elson, C. O., Weaver, C. T.: Regulatory T-cell suppression and energy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173, 7249-7258 (2004).
11. Leung, B. P., Conacher, M., Hunter, D., McInnes, I. B., Liew, F. Y., Brewer, J. M.: A novel dendritic-cell-induced model of erosive inflammatory arthritis: Distinct role of dendritic cells in T cell activation and induction of local inflammation. J Immunol 169, 7071-7077 (2002).
12. Horstmann, B., Zinser, E., Turza, N., Kerek, F., Steinkasserer, A.: MCS-18, a novel natural product isolated from Helleborus purpurascens, inhibits dendritic cell activation and prevents autoimmunity as shown in vivo using the EAE model. Immunobiology 2007 (accepted for publication).
13. Beutler, B.: Interferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257-263 (2004).
14. Blander, J. M., Medzhitov, R.: Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature Immunol 7, 1029-1035 (2006).
15. Lee, E. K., Kang, S. M., Paik, D. J., Kim, J. M., Youn, J.: Essential roles of Toll-like receptor-4 signalling in arthritis induced by type II collagen antibody and LPS. Int Immunol 17, 325-333 (2005).
16. Ruprecht, C. R., Lanzavecchia, A.: Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 36, 810-816 (2006).
17. Gay, N. J., Gangloff, M., Weber, A. N. R.: Toll-like receptors as molecular switches. Nature Rev Immunol 6, 693-698 (2006).
18. Underhill, D. M., Ozinski, A., Haijar, A. M., Stevens, A., Wilson, C. B., Bassetti, M. Aderem, A.: The Toll-like receptor-2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401, 811-815 (1999).
19. Liew, F. Y., Xu, D., Brint, E. K., ONeill, L. A. J.: Negative regulation of Toll-like receptor mediated immune responses. Nature Rev Immunol 5, 446-458 (2005).
20. Pasare, C., Medzhitov, R.: Control of B-cell responses by Toll-like receptors. Nature 438, 364-368 (2005).
21. Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C. H., Beutler, B., Nemazee, D.: Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006).
22. Bagchi, A., Herrup, E. A., Warren, H. S., Trigilio, J., Shin, H. S., Valentine, C., Hellman, J.: MyD88-Dependent and My88-independent pathways in synergy, priming and tolerance between TLR agonists. J Immunol 178, 1164-1171 (2007).
23. Rckle, T., Schwarz, M. K., Rommel, C.: PI3K inhibition towards an aspirin of the 21st century? Nat Rev Drug Discovery 5, 903-918 (2006).
24. Durbaca, S., Andronescu, C., Diaconescu, A.: Experimental study on estimating the immunogenic potency of diphtheria and/or tetanus toxoids in monovaccines and associated vaccines. Roum Arch Microbiol Immunol 55, 119-131 (1996).
25. Huet, M.: Titrage in vivo des antitoxines tetanique. Arch Inst Pasteur Tunis 2, 24-29 (1978).
26. Fritz, J. F., Ferrero, R. L., Philpott, D. J., Girardin, S. E.: NOD-Like proteins in immunity, inflammation and disease. Nature Immunology 7, 1250-1257 (2006).
27. Krieg, A. M.: Toll-free vaccines? Nature Biotechnology 25, 303-305 (2007).